Sequent Scientific Limited has announced its consolidated financial results for the December 2024 quarter, showcasing a revenue of ₹3.91 billion from operations. The company also reported a net profit of ₹34.4 million, reflecting resilience amidst challenging market conditions. These results underline Sequent Scientific's steady growth trajectory in the pharmaceutical sector, despite industry-wide pressures. The company's focus on operational efficiency and strategic initiatives continues to drive its performance.
Source: Moneycontrol.